Data Insights

Risk adjusted net present value: What is the current valuation of Roche's Ipatasertib?

Ipatasertib is a small molecule commercialized by Roche, with a leading Phase III program in Metastatic Breast Cancer;Human Epidermal Growth...

Net Present Value Model: Roche Holding AG's Ipatasertib

Data Insights

Ipatasertib by Genentech USA for Metastatic Breast Cancer: Likelihood of Approval

Ipatasertib is under clinical development by Genentech USA and currently in Phase III for Metastatic Breast Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ipatasertib in Metastatic Breast Cancer

Data Insights

Ipatasertib by Genentech USA for Solid Tumor: Likelihood of Approval

Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipatasertib in Solid Tumor

Data Insights

Ipatasertib by Genentech USA for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Ipatasertib is under clinical development by Genentech USA and currently in Phase III for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - Ipatasertib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Ipatasertib by Genentech USA for Hypopharyngeal Cancer: Likelihood of Approval

Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Hypopharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipatasertib in Hypopharyngeal Cancer

Data Insights

Ipatasertib by Genentech USA for Laryngeal Cancer: Likelihood of Approval

Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Laryngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipatasertib in Laryngeal Cancer

Data Insights

Ipatasertib by Genentech USA for Oropharyngeal Cancer: Likelihood of Approval

Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Oropharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ipatasertib in Oropharyngeal Cancer

Data Insights

Ipatasertib by Genentech USA for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval

Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Paranasal Sinus And Nasal Cavity Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - Ipatasertib in Paranasal Sinus And Nasal Cavity Cancer

Data Insights

Ipatasertib by Genentech USA for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Oral Cavity (Mouth) Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ipatasertib in Oral Cavity (Mouth) Cancer

Data Insights

Ipatasertib by Genentech USA for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - Ipatasertib in Head And Neck Squamous Cell Carcinoma (HNSC)